We tested the hypothesis that concentrations of adipocytokines are altered in SLE and associated with coronary atherosclerosis, insulin resistance and inflammation. Concentrations of resistin, leptin, adiponectin and visfatin were measured in 109 patients with SLE and 78 control subjects. Coronary calcification was measured using electron beam-computed tomography, and insulin resistance was defined by the homeostasis model assessment index. Concentrations of adiponectin (28.7 ± 17.9 vs 22.0 ± 15.3 μg/mL, P = 0.003), leptin (41.1 ± 49.9 vs 19.8 ± 24.6 ng/mL, P < 0.001) and visfatin (7.5 ± 10.5 vs 4.5 ± 2.8 ng/mL, P < 0.001) were higher in patients with SLE than in controls. These differences remained significant after adjustment for age, race, sex and body mass index (BMI; all P values < 0.02). Concentrations of resistin (10.7 ± 7.6 vs 9.1 ± 5.1 ng/mL, P = 0.41) did not differ in patients and controls. In patients with SLE, leptin was positively associated with BMI (ρ = 0.80, P < 0.001), insulin resistance (ρ = 0.46, P < 0.001) and C-reactive protein (CRP) (ρ = 0.30, P = 0.002), whereas adiponectin was negatively associated with the same factors (ρ = -0.40, P < 0.001; ρ = −0.38, P < 0.001; ρ = -0.22, P = 0.02, respectively). None of the adipocytokines were associated with coronary atherosclerosis in SLE. In conclusion, patients with SLE have increased concentrations of adiponectin, leptin and visfatin. Lower concentrations of adiponectin and higher concentrations of leptin are associated with insulin resistance, BMI and CRP in patients with SLE. Lupus (2009) 18, 799-806.
Introduction
Adipose tissue has endocrine functions and is the main source of several mediators, termed adipocytokines, which include leptin, resistin, visfatin and adiponectin. These adipocytokines have profound effects on glucose homeostasis, appetite regulation, inflammation and atherosclerosis. 1 Leptin, resistin and visfatin have pro-inflammatory and atherogenic effects and are associated with insulin resistance. 1, 2 For example, increased concentrations of these three adipocytokines are found in animal models of obesity and in individuals with diabetes, 1 and higher concentrations of resistin and leptin are associated with coronary atherosclerosis and coronary events. 3, 4 Adiponectin, however, has anti-diabetic, anti-inflammatory and anti-atherogenic effects. 1, 5 Lower concentrations of adiponectin are found in patients with diabetes or the metabolic syndrome 6 and are associated with the presence and progression of coronary atherosclerosis, independent of traditional cardiovascular risk factors. 5 Thus, adipocytokines may provide a mechanistic link among impaired insulin sensitivity, obesity, chronic inflammation, and atherosclerosis. We have reported that patients with systemic lupus erythematosus (SLE) frequently meet the criteria for the metabolic syndrome 7 and have accelerated atherosclerosis 8 and a higher prevalence of insulin resistance. 7 Little is known about adipocytokines in SLE. 9 We therefore examined the hypothesis that concentrations of adipocytokines are altered in SLE and associated with coronary atherosclerosis, insulin resistance and inflammation.
Methods
We studied 109 patients with SLE and 78 control subjects who are participating in ongoing clinical investigations into the prevalence and mechanisms of atherosclerosis. 7, 8, [10] [11] [12] Eligible patients with SLE included individuals who met the criteria for SLE, 13 were over 18 years of age and had a disease duration of 1 year or greater. The controls did not meet the criteria for SLE or any other autoimmune disease and were frequency matched to the patients with SLE for age, sex and race. Patients were recruited from local rheumatologists in Nashville, Tennessee, USA, from advertisements and from a Lupus Foundation newsletter. Six patients with SLE were excluded because of a history of myocardial infarction, angina or stroke. Controls were recruited from advertisements and patients' acquaintances, and a database was maintained by the General Clinical Research Center at Vanderbilt University School of Medicine, Nashville, Tennessee, USA. Control subjects who had a history of myocardial infarction, angina, or stroke were excluded. All subjects provided a written informed consent, and the Institutional Review Board of Vanderbilt University Hospital approved the study.
Patient assessment included a standardised interview, physical examination, laboratory tests and, in patients, a review of medical records. The use of current and cumulative medications was determined by both chart review and the standardised interview. Body mass index (BMI) was calculated using the attained height and weight measurements and waist circumference measured. Blood pressure was determined, as the average of two measurements was recorded 5 min apart after subjects had rested supine for 10 min. Subjects were considered to be hypertensive if they were taking anti-hypertensive medications, if their systolic blood pressure was 140 mmHg, or if their diastolic blood pressure was 90 mmHg or higher. After an overnight fast, a blood sample was taken to measure high-density lipoprotein (HDL), total cholesterol, triglycerides, glucose and insulin. Subjects were considered to be diabetic if they were taking antidiabetic medications or if their glucose levels were above 126 mg/dL. Low-density lipoprotein (LDL) was calculated. Insulin, leptin, adiponectin, resistin, tumour necrosis factor (TNF)-α, interleukin (IL)-6, IL-1a (Linco/Millipore Corp., Missouri, USA) and visfatin (Phoenix Pharmaceuticals, Inc., California, USA) concentrations were measured using ELISA. In patients with SLE, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were determined. Additionally, for patients with SLE, disease activity and damage were measured using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and the Systemic Lupus International Collaborating Clinics Damage Index (SLICC), respectively. 14, 15 To measure coronary atherosclerosis, subjects underwent chest computed tomography imaging with an Imatron C-150 scanner (GE/Imatron, South San Francisco, California, USA) as described previously. 8, 16 Briefly, imaging was performed with a 100-ms scanning time and a single-slice thickness of 3 mm. Forty slices were obtained during a single breath-holding period starting at the aortic arch and proceeding to the level of the diaphragm. All scans were scored, as described by Agatston, et al. 17 by a single experienced investigator (PR), unaware of the subjects' clinical status.
Patients and control subjects were classified as having the metabolic syndrome based on the definition set forth by the World Health Organization (WHO). The modified WHO definition requires the presence of insulin resistance, which is defined by any of the following: a homeostasis model assessment (HOMA) index (fasting glucose [mmol/L] × fasting insulin [μU/mL]/22.5) in the top quartile of a non-diabetic population, impaired fasting glucose (≥110 mg/dL) or diabetes. In addition to insulin resistance, the WHO definition also requires two of the three following criteria: central obesity (waist >94 cm in men and >88 cm in women), elevated triglycerides (≥150 mg/dL or HDL <35 mg/dL in men and <40 mg/dL in women), and high blood pressure, defined as ≥140/90 mmHg, or the use of hypertensive medications. Based on the Study of Inherited Risk of Coronary Atherosclerosis (SIRCA) data, 18 a HOMA index of >2.114 was defined as representative of the top quartile of a nondiabetic population.
Demographic characteristics are presented as mean and standard deviation (SD) for continuous variables or as frequencies and percentages for categorical variables. The differences between cases and controls were determined using Wilcoxon rank sum test or Fisher's exact test, as appropriate. Adipocytokine concentrations are presented as mean (±SD) and compared in patients with lupus and control subjects using Wilcoxon rank sum tests. Further, to assess whether these differences were independent of age, race, sex and BMI, linear regressions with adipocytokines (after logarithmic transformation to achieve normal distribution of the residuals) as the dependent variable and disease status (either SLE or control) as the independent variable were modelled. We used Spearman correlations to examine the association between adipocytokines and clinical variables, markers of inflammation and disease characteristics. We used logistic regression to examine the association between the metabolic syndrome and adipocytokines in patients with SLE. Adipocytokines were logarithmically transformed, and results are expressed as odds ratios and 95% confidence interval and are further adjusted for CRP and BMI (except for the model including obesity that was only adjusted for CRP). Logistic regressions were modelled to examine the association between adipocytokines as independent variable and coronary artery atherosclerosis as dependent variable. To assess whether the association between adipocytokines and coronary atherosclerosis was independent of traditional risk factors, multivariable regressions were modelled using pre-specified covariates that are known to be strongly associated with the outcomes of interest (age, race, sex, BMI and Framingham risk score). All analyses used a two-sided significance level of 5% and were performed using STATA 9.1.
Results

Patients and control subjects
Patients with lupus and control subjects were of similar age (40.2 ± 11.5 and 40.5 ± 12.0 years, respectively, P = 0.86) and sex (91.7 and 85.9% female, respectively, P = 0.24). In all, 74 (68%) patients with lupus and 57 (73%) control subjects were Caucasian. There was a trend toward higher BMI in patients with lupus (29.2 ± 7.5 kg/m 2 ) than in controls (27.0 ± 6.0 kg/m 2 , P = 0.05), and the HOMA index was significantly higher in patients (2.0 ± 1.8 units) than in controls (1.5 ± 1.0 units, P = 0.04) ( Table 1 ). The mean disease duration of SLE was 8.2 ± 7.3 years, the mean SLEDAI was 4.1 ± 4.0 and the mean SLICC was 0.9 ± 1.3. Patients with SLE had a mean ESR of 26.9 ± 27.5 mm/h and CRP of 6.3 ± 9.1 mg/L.
Adipocytokines in patients with SLE and controls
As shown in Figure 1 , concentrations of adiponectin (28.7 ± 17.9 vs 22.0 ± 15.3 μg/mL, P = 0.003), leptin (41.1 ± 49.9 vs 19.8 ± 24.6 ng/mL, P < 0.001) and visfatin (7.5 ± 10.5 vs 4.5 ± 2.8 ng/mL, P < 0.001) were higher in patients with SLE than in controls. These differences between patients with lupus and control subjects remained significant after adjustment for age, race, sex and BMI (all P values < 0.02). There were no significant differences in concentrations of resistin between patients and control subjects (10.7 ± 7.6 and 9.1 ± 5.1 ng/mL, respectively, P = 0.41).
Cardiovascular risk factors and adipocytokines
In patients with SLE, adiponectin was significantly negatively correlated with BMI (ρ = −0.40) and positively correlated with HDL cholesterol (ρ = 0.38) ( Table 2) . Leptin correlated significantly with BMI (ρ = 0.80), total cholesterol (ρ = 0.25), LDL choles-terol (ρ = 0.21) and triglycerides (ρ = 0.22) ( Table 2) . Visfatin was not significantly associated with any cardiovascular risk factor. Similar results were found in control subjects; adiponectin was significantly negatively correlated with BMI (ρ = −0.54), and leptin was significantly positively correlated with BMI (ρ = 0.70). nor SLICC scores were associated with adipocytokine concentrations ( Table 3 ). There were 27 (24.8%) patients receiving hormone replacement therapy (HRT), 8 (7.4%) patients taking statins and 64 (59%) patients taking corticosteroids. Concentrations of leptin were higher in patients receiving HRT (50.5 ± 47.8 compared to 38.1 ± 50.5 ng/mL, P = 0.03). Adipocytokine concentrations were not related to current use of immunosuppressive therapy (defined as use of cyclophosphamide, azathioprine, mycophenolate or methotrexate). Concentrations of adiponectin (P = 0.85), resistin (P = 0.40), leptin (P = 0.12) and visfatin (P = 0.82) were not significantly different in patients with SLE who were receiving immunosuppressive therapy and those who were not. There were no other statistically significant differences in adipocytokine concentrations related to current use of HRT, corticosteroids or statins. Furthermore, cumulative exposure to corticosteroids was not significantly correlated with adipocytokine concentrations (Table 3) .
Disease characteristics and adipocytokines in SLE
Insulin resistance, the metabolic syndrome, and coronary atherosclerosis and adipocytokines in SLE
Lower concentrations of adiponectin were significantly associated with the presence of insulin resistance (P = 0.001) ( Table 4 ). This association was not significant after adjusting for BMI (P = 0.14) and BMI and CRP (P = 0.13). Higher concentrations of leptin were significantly associated with insulin resistance (P < 0.001) but were not significant after adjusting for BMI (P = 0.77) and BMI and CRP (P = 0.47). Neither resistin nor visfatin was associated with insulin resistance (Table 4 ). Higher concentrations of leptin were also associated with the presence of the metabolic syndrome and its several individual components (obesity, insulin resistance and hypertension). In contrast, higher concentrations of adiponectin were inversely related to the presence of the metabolic syndrome and to the components of obesity, insulin resistance and dyslipidemia.
There was no association between coronary calcification and adipocytokines (Table 5 ). After statistical Adipocytokines were logarithmically transformed. a Results are adjusted for C-reactive protein (CRP) and body mass index (except for the model including obesity that was only adjusted for CRP).
adjustment for age and sex, the association between resistin and coronary artery calcification was of borderline significance (P = 0.06) but not after adjustment for Framingham risk score (P = 0.20).
Discussion
The main findings of this study are that patients with SLE have increased concentrations of adiponectin, leptin and visfatin and these are independent of BMI. Lower concentrations of adiponectin and higher concentrations of leptin are associated with insulin resistance. Furthermore, none of the adipocytokines studied were associated with coronary atherosclerosis in SLE.
Mutations resulting in loss of function of the leptin receptor are associated with increased appetite, obesity and hyperglycemia, but leptin concentrations are increased in obesitya paradox thought to reflect 'leptin resistance'. 19 Recent information that CRP binds to leptin, impairs signalling and mediates leptin resistance 20 suggests that leptin resistance may be more likely in the setting of chronic inflammation. Indeed, leptin and CRP concentrations were independently associated in healthy volunteers. 21 Leptin also induces CRP expression in vitro 22 and is both proinflammatory 21 and atherogenic 23 ; increased concentrations are associated with insulin resistance and are an independent risk factor for coronary heart disease. 4 There is little information about leptin in SLE. Leptin concentrations were higher in patients than in controls, 9, 24 suggesting a relationship between leptin and lupus disease-related factors. We found that leptin concentrations were increased in SLE, and as would be expected, leptin was strongly associated with BMI. We also showed, for the first time in SLE, an association between leptin and insulin resistance, the metabolic syndrome, CRP, ESR, LDL cholesterol and triglycerides. Although leptin was strongly associated with obesity in SLE, the difference in leptin concentrations between patients with lupus and controls was independent of age, race, sex and BMI, suggesting that additional factors drive leptin production or alter the relationship between obesity and leptin in lupus.
Visfatin is a recently discovered adipocytokine that binds to the insulin receptor and is thought to be secreted to compensate for insulin resistance. 25 It is also pro-inflammatory and associated with unstable atherosclerotic lesions. 26 In addition to its potential role in glucose metabolism and atherosclerosis, visfatin has been linked with inflammation and concentrations are increased in patients with rheumatoid arthritis (RA). 27 To the best of our knowledge, there is no information about visfatin in SLE. Visfatin concentrations were significantly higher in patients with SLE than in controls but were not associated with metabolic or inflammatory measures. This is concordant with some recent population studies, including the Framingham Offspring Cohort, which found no relationship between visfatin concentrations and metabolic variables. 28 Visfatin, previously known as pre-B-cell colony enhancing factor, activates human leukocytes and stimulates the production of cytokines such as IL-6. 25 Thus, although not associated with the inflammatory mediators and markers we measured, the elevated concentrations of visfatin observed could reflect inflammation in SLE.
Resistin mediates obesity-induced insulin resistance in a mouse model of obesity. 29 The administration of anti-resistin antibodies improved blood glucose and insulin action, and rosiglitazone, an anti-diabetic drug, decreased resistin concentrations in an animal model. 30 In humans, resistin has been associated with obesity, diabetes and inflammation in some studies. 3, 31 However, its role in SLE is poorly defined. We did not find a statistically significant difference in resistin concentrations between patients with SLE and control subjects. Consistent with our data, concentrations of resistin in patients with RA were not higher than in controls, although there were differences in leptin, adiponectin and visfatin. 27 We found a relatively weak association between resistin and ESR but no association with CRP, IL-6, TNF and HOMA. These findings are largely compatible with those of the SIRCA study that found no relationship between resistin and HOMA and only a weak association with CRP and IL-6 (ρ = 0.10 and 0.16, respectively) in a community-based sample of asymptomatic subjects from the general population. 3 Adiponectin is secreted by adipose tissue, but in contrast to leptin, resistin and visfatin, adiponectin has anti-diabetic, anti-inflammatory and anti-atherogenic effects. 1, 5 Adiponectin acts as an insulin sensitiser 1 and decreases the inflammatory response induced by TNF-α. 32 Thus, low concentrations of adiponectin are associated with obesity, insulin resistance and dyslipidemia. 32, 33 Patients with SLE have higher concentrations of adiponectin than controls, 9 and we show that despite this increase, the inverse relationships between adiponectin and BMI, HOMA, metabolic syndrome, systolic blood pressure and dyslipidemia persist in SLE. Thus, the increase in adiponectin concentrations in SLE might reflect a partial compensatory response to these metabolic perturbations.
In addition to their role in mediating the metabolic and inflammatory changes associated with obesity, adipocytokines may play a role in atherogenesis. Leptin concentrations are associated with risk of coronary events 4 and in type 2 diabetics associated with coronary calcification. 34 Similarly, resistin concentrations are associated with coronary calcification 3 and carotid intima-media thickness. 35 Conversely, low concentrations of adiponectin are associated with increased risk of myocardial infarction and progression of coronary calcification. 5, 36 In our patients with SLE, although concentrations of leptin were elevated and atherosclerosis was accelerated, 8 we found no relationship between concentrations of adipocytokines and coronary calcification. There are several possible explanations. First, other unidentified risk factors may drive atherosclerosis in SLE and obscure the effect of adipocytokines. Second, the increased concentrations of adiponectin could offset the adverse cardiovascular effects of increased concentrations of leptin. This appears to be unlikely because we also examined the leptin:adiponectin ratioa parameter that may provide a better measure of atherogenic risk than either adipocytokine alone 37 and found no relationship to coronary calcification.
Our data suggest that adipocytokines are associated with inflammatory markers but not with disease activity, as measured with the SLEDAI score. Although perhaps counterintuitive, the correlation between the SLEDAI score and laboratory markers of inflammation is relatively weak, for example, in our population, the correlation between SLEDAI and ESR and CRP (r = 0.21 for both) explained only approximately 4% of the variance.
This study has some limitations. First, our observations are based on a cross-sectional analysis rather than a longitudinal analysis, and thus the analysis only includes a single measurement of adipocytokines. Multiple measurements of adipocytokines over time are likely to provide additional information. Second, this is a population with relatively low disease activity, and therefore, our findings may not be applicable to patients with very active disease.
In conclusion, patients with SLE have higher concentrations of adiponectin, leptin and resistin. Leptin (positively) and adiponectin (negatively) were associated with BMI, insulin resistance, CRP and the metabolic syndrome. Coronary calcification was not related to adipocytokines. Adipocytokines may provide a link between insulin resistance and inflammation in SLE.
